期刊文献+

应用MDCK-MDR1细胞模型研究3-乙酰基-11-羰基-b-乙酰乳香酸经血脑屏障的通透性 被引量:4

Study on the permeation of acetyl-11-keto-beta-boswellic acid through blood-brain barrier by MDCK-MDR1 cell model
原文传递
导出
摘要 目的:考察3-乙酰基-11-羰基-b-乙酰乳香酸(AKBA)经血脑屏障的通透性。方法:采用MD-CK-MDR1细胞单层模型研究AKBA的双向跨膜转运,采用LC-MS/MS分析方法测定AKBA的浓度,计算其表观渗透系数(Papp)。结果:咖啡因吸收方向Papp为(18.65±1.94)×10-6cm.s-1,罗丹明123外排率(RE)为19.96,接收室HBSS中可以检测到AKBA,且AKBA的RE<2。结论:MDCK-MDR1模型的形态、通透性、P-糖蛋白功都与血脑屏障相似。AKBA不是P-糖蛋白的底物,主要通过被动扩散透过血脑屏障,但透过率比较低。 Objective : To research the permeation of acetyl-11-keto-beta-boswellic acid (AKBA) through blood-brain barrier. Methods: MDCK-MDR1 cell monolayer model was used to study the bi-directions transport of AKBA; the concentration of AKBA was measured by LC-MS/MS and apparent permeability coefficient (Papp) was calculated. Results: The Papp of caffeine and RE of rhodamine were ( 18.65 ± 1.94) ×10-6 cm· s-1 and 19.96, respectively. AKBA was detected in the receiving chamber with RE 〈 2. Conclusion: MDCK-MDR1 model is high- ly similar to blood-brain barrier in terms of conformation, permeability and P-gp functions. Although AKBA was demonstrated to be able to penetrate blood-brain barrier though passive diffusion, the penetration rate was very low, suggesting that AKBA might not be the substrate of P-gp.
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第10期1125-1129,共5页 Chinese Journal of New Drugs
基金 国家"重大新药创制"科技重大专项(2012ZX09304002) 国家973项目(2010CB735602)
关键词 MDCK-MDR1细胞 血脑屏障 P-糖蛋白 表观渗透系数 MDCK-MDR1 cell blood-brain barrier P-gp apparent permeability coefficient
  • 相关文献

参考文献10

  • 1LOESCHER W, POTSCHKA H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases [ J ]. Prog Neurobiol, 2005, 76 ( 1 ) :22 - 76.
  • 2PASTAN I, GOTTESMAN MM, UEDA K, et al. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polar- ized expression of P-glycoprotein in MDCK cell [ J ]. Proc Natl Acad Sci USA, 1988, 85(12) :4486 -4490.
  • 3POLLI JW, WRING SA, HUMPHREYS JE, et al. Rational use of in vitro P-glycoprotein assays in drug discovery[J]. Pharmacol Exp Ther, 2001, 299(2) :620 -628.
  • 4郑虎占,董泽宏,余靖.中药现代研究与应用(三册)[M].北京:学苑出版社,1997:2967-2977.
  • 5KR1]GER P, KANZER J, HUMMEL J, et al. Permeation of Bo- swellia extract in the caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1 B3 and MRP2 [ J]. Eur J Pharm Scl, 2009,36(2 -3) : 275 -284.
  • 6SAILER ER, SUBRAMANIAN LR, RALL B, et al. Acetyl-11- keto-beta-boswellic acid ( AKBA ) : structure requirements for binding and 5-1ipoxygenase inhibitory activity[ J]. Br J Pharma- col, 1996, 117(4):615-618.
  • 7INTERNATIONAL TRANSPORTER CONSORTIUM, GIACOMI- NI KM, HUANG SM, et al. Membrane transporters in drug de- velopment[ J ]. Nat Rev Drug Discov, 2010, 9 ( 3 ) : 215 - 236.
  • 8IRVINE JD, TAKAHASHI L, LOCKHARD K, et al. MDCK ( Madin-Darby canine kidney) ceils: a tool for membrane perme- ability screening[ J]. J Pharm Sci, 1999, 88 ( 1 ) :28 - 33.
  • 9LOESCHER W, POTSCHKA H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases [ J ]. Prog Neurobiol, 2005, 76 ( 1 ) :22 -76.
  • 10HOSOYA K, SUMIO O, TETSUYA T. Recent advances in the brain-to-blood efflux transport across the blood-brain barrier[ J]. lnt J Pharm, 2002, 248(1 -2) :15 129.

同被引文献44

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部